methyl (E)-3-naphthalen-2-ylsulfonylprop-2-enoate

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: methyl (E)-3-naphthalen-2-ylsulfonylprop-2-enoate
• 化学式: C₁₄H₁₂O₄S
• 分子量: 276.31
• InChiKey: OUCBQFLJRUKAIQ-CMDGGOBGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.071
• 拓扑面积：
  68.8
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Nrf2 Activating Compounds and Uses Thereof
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：US20170217922A1

  公开（公告）日：2017-08-03

  Aspects of the present disclosure include compounds that activate Nrf2. Such compounds find use in the treatment of autoimmune and inflammatory diseases and disorders, such as for example psoriasis and multiple sclerosis. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  本公开涉及激活Nrf2的化合物，这些化合物可用于治疗自身免疫和炎症性疾病和疾患，例如牛皮癣和多发性硬化症。本公开实施例还涉及包括这些化合物的制药组合物，使用这些化合物治疗各种疾病和疾患的方法，制备这些化合物的过程以及这些过程中有用的中间体。
• Nrf2 activating compounds and uses thereof
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：US10844040B2

  公开（公告）日：2020-11-24

  Aspects of the present disclosure include compounds that activate Nrf2. Such compounds find use in the treatment of autoimmune and inflammatory diseases and disorders, such as for example psoriasis and multiple sclerosis. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  本公开的各个方面包括激活 Nrf2 的化合物。 这些化合物可用于治疗自身免疫性和炎症性疾病，例如牛皮癣和多发性硬化症。 本公开的实施方案还涉及包括这些化合物的药物组合物、使用这些化合物治疗各种疾病和失调的方法、制备这些化合物的工艺以及在这些工艺中有用的中间体。
• NRF2 ACTIVATING COMPOUNDS AND USES THEREOF
  申请人：Rigel Pharmaceuticals, Inc.

  公开号：EP3411361A1

  公开（公告）日：2018-12-12
• Inhibitors of PFKFB3 for Cancer Therapy
  申请人：Lee Yong-Hwan

  公开号：US20120302631A1

  公开（公告）日：2012-11-29

  Compounds used to inhibit glycolytic pathway small molecule kinase 6-Phosphofructo-2-kinase/Fructose-2,6-bisphosphatase (PFKFB) are set forth; these inhibitors can be used in the treatment of certain diseases in which cells or tumors rely on glycolytic metabolism, such as many cancer cells.
• US9492418B2
  申请人：——

  公开号：US9492418B2

  公开（公告）日：2016-11-15